34 filings
Page 2 of 2
8-K
3vvyvmqbjynsux 54mi
16 Jun 21
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
4:29pm
8-K
9fgzv2ijh
2 Jun 21
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
x9b22ft
11 May 21
Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results
4:05pm
8-K
lnjl7
25 Mar 21
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
5:02pm
8-K
dnm6ef a45besr
1 Mar 21
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
12:00am
8-K
yhzwx
10 Nov 20
Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
4:21pm
8-K
zhf938x 490e94eb9
10 Sep 20
Other Events
4:40pm
8-K
hgs081af
11 Aug 20
Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
4:10pm
8-K
6dtz8
7 Jul 20
Departure of Directors or Certain Officers
4:12pm
8-K
12o6mcu0 kpuxrp
15 Jun 20
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
nu7ebh
12 May 20
Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results
4:30pm
8-K
79fuyc3ly
10 Mar 20
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Results
4:10pm
8-K
x4kbui4
12 Nov 19
Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results
4:16pm
8-K
q0odh7bvjij1v 79sw6
17 Sep 19
Satsuma Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
4:11pm